Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay.

Laeyendecker O, Brookmeyer R, Oliver AE, Mullis CE, Eaton KP, Mueller AC, Jacobson LP, Margolick JB, Brown J, Rinaldo CR, Quinn TC, Eshleman SH; Multicenter Aids Cohort Study Macs..

AIDS Res Hum Retroviruses. 2012 Aug;28(8):816-22. doi: 10.1089/AID.2011.0258.

2.

Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.

Laeyendecker O, Brookmeyer R, Mullis CE, Donnell D, Lingappa J, Celum C, Baeten JM, Campbell MS, Essex M, de Bruyn G, Farquhar C, Quinn TC, Eshleman SH; Partners in Prevention HSV/HIV Transmission Study Team..

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1177-83.

3.

HIV incidence determination in the United States: a multiassay approach.

Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Mehta SH, Astemborski J, Jacobson LP, Margolick JB, Brown J, Quinn TC, Eshleman SH.

J Infect Dis. 2013 Jan 15;207(2):232-9. doi: 10.1093/infdis/jis659.

4.

Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy.

Marinda ET, Hargrove J, Preiser W, Slabbert H, van Zyl G, Levin J, Moulton LH, Welte A, Humphrey J.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):496-9.

PMID:
20306555
5.

Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay.

Longosz AF, Mehta SH, Kirk GD, Margolick JB, Brown J, Quinn TC, Eshleman SH, Laeyendecker O.

AIDS. 2014 May 15;28(8):1227-32. doi: 10.1097/QAD.0000000000000221.

6.

Decreased specificity of an assay for recent infection in HIV-1-infected patients on highly active antiretroviral treatment: implications for incidence estimates.

Chaillon A, Le Vu S, Brunet S, Gras G, Bastides F, Bernard L, Meyer L, Barin F.

Clin Vaccine Immunol. 2012 Aug;19(8):1248-53. doi: 10.1128/CVI.00120-12.

7.

[A system review on the application of BED-capture enzyme immunoassay in detecting new HIV-1 infection].

Tao J, Zhao J, Liu Y, Meng LZ, Yu SC, Jiang Y, Xiao Y.

Zhonghua Liu Xing Bing Xue Za Zhi. 2011 Feb;32(2):177-81. Review. Chinese.

PMID:
21518629
8.

Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.

Longosz AF, Serwadda D, Nalugoda F, Kigozi G, Franco V, Gray RH, Quinn TC, Eshleman SH, Laeyendecker O.

AIDS Res Hum Retroviruses. 2014 Apr;30(4):339-44. doi: 10.1089/AID.2013.0169.

9.

Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay.

Hayashida T, Gatanaga H, Tanuma J, Oka S.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):495-8. doi: 10.1089/aid.2007.0150.

PMID:
18327979
10.

Response to highly active antiretroviral therapy according to duration of HIV infection.

Pezzotti P, Pappagallo M, Phillips AN, Boros S, Valdarchi C, Sinicco A, Zaccarelli M, Rezza G; Italian Seroconversion Study..

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):473-9.

PMID:
11391168
11.

Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa.

Karita E, Price M, Hunter E, Chomba E, Allen S, Fei L, Kamali A, Sanders EJ, Anzala O, Katende M, Ketter N; IAVI Collaborative Seroprevalence and Incidence Study Team..

AIDS. 2007 Feb 19;21(4):403-8.

PMID:
17301558
12.

Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda.

Mullis CE, Munshaw S, Grabowski MK, Eshleman SH, Serwadda D, Brookmeyer R, Nalugoda F, Kigozi G, Kagaayi J, Tobian AA, Wawer M, Gray RH, Quinn TC, Laeyendecker O.

AIDS Res Hum Retroviruses. 2013 Aug;29(8):1146-50. doi: 10.1089/AID.2012.0105.

13.
14.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network..

J Infect Dis. 2006 Sep 15;194(6):725-33.

PMID:
16941337
15.

Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.

Konikoff J, Brookmeyer R, Longosz AF, Cousins MM, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Justman JE, Hodder SL, Quinn TC, Eshleman SH, Laeyendecker O.

PLoS One. 2013 Dec 27;8(12):e82772. doi: 10.1371/journal.pone.0082772.

16.

Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.

Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Brookmeyer R, Quinn TC, Laeyendecker O.

PLoS One. 2013;8(2):e55525. doi: 10.1371/journal.pone.0055525.

17.

Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort.

Hauser A, Santos-Hoevener C, Meixenberger K, Zimmermann R, Somogyi S, Fiedler S, Hofmann A, Bartmeyer B, Jansen K, Hamouda O, Bannert N, Kuecherer C.

PLoS One. 2014 Jun 3;9(6):e98038. doi: 10.1371/journal.pone.0098038.

18.

Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.

Longosz AF, Morrison CS, Chen PL, Arts E, Nankya I, Salata RA, Franco V, Quinn TC, Eshleman SH, Laeyendecker O.

J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):390-6. doi: 10.1097/QAI.0000000000000006.

19.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, ViganĂ² P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group.; Italian Cohort Naive for Antiretrovirals Study Group..

Clin Infect Dis. 2005 Jun 15;40(12):e101-9.

PMID:
15909251
20.

Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.

Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA.

Med Care. 2005 Sep;43(9 Suppl):III15-22.

PMID:
16116305
Items per page

Supplemental Content

Support Center